Statera Biopharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Statera Biopharma generated cash of -$28,193,283, which is less than the previous year. Cash used in financing activities reached the amount of $20,987,808 last year. Net change in cash is therefore $6,250,863.
Cash Flow
| 2013 | -23.10B | 560.70M | 7.26B |
|---|---|---|---|
| 2014 | -14.45B | -1.78B | 10.59B |
| 2015 | -12.08M | -10.27M | 24.93M |
| 2016 | -5.03M | 5.67M | 539.99K |
| 2017 | -6.61M | 3.88M | 0 |
| 2018 | -4.61M | 3.96M | 55.21K |
| 2019 | -240.37K | 156.78K | 231K |
| 2020 | -5.08M | -9.63K | 5.68M |
| 2021 | -28.19M | 13.46M | 20.98M |
STAB Cash Flow Statement (2013 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 593.86K | 1.65K | 11.02K | 4.23M | 6.90M | 5.91M | 3.10M | 10.04B | 25.65B |
Operating activities | |||||||||
Net income | -101.87M | -12.09M | -3.22M | -3.70M | -9.84M | -2.59M | -13.04M | 35.36M | -20.12B |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 255.57K | 1.03K | 13.78K | 18.17K | 21.08K | 63.45K | 140.13K | 200.79M | 376.21M |
Stock-based compensation expense | 6.05M | 2.69M | 0 | 0 | 0 | 0 | 96.40K | 0 | 1.47B |
| Deferred income tax benefit | 6.05M | 2.69M | 0 | 0 | 0 | 0 | 96.40K | 0 | 1.47B |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | -352.09K | 380.14K | -68.47K | 431.32K | -201.76K | 300.76K | -414.06K | 629.39M | -416.49M |
Inventories | -1.00M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 1.00M | -225.17K | 196.52K | -325.83K | -138.57K | 124.00K | -833.94K | 459.33M | -713.50M |
Cash generated by operating activities | -28.19M | -5.08M | -240.37K | -4.61M | -6.61M | -5.03M | -12.08M | -14.45B | -23.10B |
Investing activities | |||||||||
Purchases Of Investments | 0 | -679.17K | -1.24M | -7.73M | -8.63M | -17.22M | -16.87M | -1.40B | 0 |
Investments In Property Plant And Equipment | -182.97K | -9.63K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 13.64M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 13.46M | -9.63K | 156.78K | 3.96M | 3.88M | 5.67M | -10.27M | -1.78B | 560.70M |
Financing activities | |||||||||
Common Stock Issued | 7.34M | 2.78M | 0 | 0 | 0 | 539.99K | 27.19M | 9.69B | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -897.73K | 0 | 231K | 0 | 0 | 0 | 0 | -4.17B | 0 |
Cash used in financing activities | 20.98M | 5.68M | 231K | 55.21K | 0 | 539.99K | 24.93M | 10.59B | 7.26B |
Net Change In Cash | 6.25M | 592.21K | -9.37K | -613.31K | -2.67M | 983.39K | 2.81M | -6.94B | -15.60B |
Cash at end of period | 6.84M | 593.86K | 1.65K | 3.61M | 4.23M | 6.90M | 5.91M | 3.10B | 10.04B |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |